Bryn Mawr Trust Advisors LLC Sells 1,049 Shares of Eli Lilly and Company $LLY

Bryn Mawr Trust Advisors LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 23.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 3,434 shares of the company’s stock after selling 1,049 shares during the period. Bryn Mawr Trust Advisors LLC’s holdings in Eli Lilly and Company were worth $3,159,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LLY. Bleakley Financial Group LLC increased its holdings in shares of Eli Lilly and Company by 6.9% during the first quarter. Bleakley Financial Group LLC now owns 38,452 shares of the company’s stock worth $35,367,000 after buying an additional 2,482 shares in the last quarter. Illumine Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.4% during the 1st quarter. Illumine Investment Management LLC now owns 600 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares in the last quarter. Birinyi Associates Inc. grew its position in Eli Lilly and Company by 12.9% during the 1st quarter. Birinyi Associates Inc. now owns 1,191 shares of the company’s stock worth $1,095,000 after acquiring an additional 136 shares during the last quarter. Center for Financial Planning Inc. grew its position in Eli Lilly and Company by 16.4% during the 1st quarter. Center for Financial Planning Inc. now owns 915 shares of the company’s stock worth $842,000 after acquiring an additional 129 shares during the last quarter. Finally, TFR Capital LLC. increased its holdings in Eli Lilly and Company by 4.7% in the 1st quarter. TFR Capital LLC. now owns 5,586 shares of the company’s stock worth $5,138,000 after purchasing an additional 249 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.3%

NYSE LLY opened at $1,154.27 on Wednesday. The stock has a market capitalization of $1.09 trillion, a P/E ratio of 41.00, a P/E/G ratio of 1.44 and a beta of 0.51. The business has a 50 day simple moving average of $1,106.93 and a 200 day simple moving average of $1,034.58. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts expect that Eli Lilly and Company will post 35.5 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LLY shares. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, Sanford C. Bernstein upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,271.93.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly won full FDA approval for selpercatinib in solid tumors, a regulatory win that could support future oncology revenue and reinforces the strength of Lilly’s pipeline. Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
• Positive Sentiment: Wall Street sentiment remains constructive, with Guggenheim raising its price target on Lilly and maintaining a buy rating, while other recent reports highlighted bullish analyst views and momentum around the company’s pipeline. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with articles noting that its weight-loss drugs now account for a very large share of revenue, underscoring how central that growth engine remains for the stock. Here’s How Much Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
• Neutral Sentiment: Lilly has been presenting new Kisunla data at the Alzheimer’s Association International Conference, which keeps attention on its dementia pipeline but does not yet appear to have delivered a clear market-moving surprise. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Neutral Sentiment: Commentary on whether Lilly’s shares can climb much higher has added to trading interest, but this is largely market speculation rather than a new fundamental catalyst. Is Lilly Stock On Track To Hit $2,090?
• Negative Sentiment: Despite the positive pipeline and analyst backdrop, traders are reacting to signs of weakness in LLY shares versus the broader market, suggesting some profit-taking or rotation out of the name. Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: One article flagged a “disturbing trend” in the billion-dollar obesity-drug market as Lilly prepares to roll out its new weight-loss pill, hinting at rising scrutiny of competition and execution risk in its most important growth category. Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.